Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective

Hepatobiliary & Pancreatic Diseases International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles